Alteration in the expression of invasion/metastasis-related melanoma cell adhesion molecule (MelCAM) is strongly associated with the acquisition of malignancy by human melanoma. However, little is known about the molecular and biochemical mechanisms that regulate the expression and function of MelCAM, or its downstream signaling transduction. In this study, we show that there is a reciprocal regulation loop between AKT and MelCAM. Pharmacological inhibition of AKT in human melanoma cell lines substantially reduced the expression of Mel-CAM. Overexpression of constitutively active AKT upregulated the levels of MelCAM in melanoma cell lines, whereas expression of a dominant-negative PI-3 kinase downregulated MelCAM. On the other hand, overexpression of MelCAM activated endogenous AKT and inhibited proapoptotic protein BAD in melanoma cells, leading to increased survival under stress conditions. Constitutive activation of AKT was observed in most melanoma cell lines and tumor samples of different progression stages. These data link AKT activation with MelCAM expression, and implicate that intervention of MelCAM-AKT signaling axis in melanoma is a potential therapeutical approach.
Introduction
Human cutaneous melanoma is one of the deadliest diseases and its incidence rate, in contrast to most other cancer types, has been rising for decades (Parker et al., 1997; Li and Herlyn, 2000; Ries et al., 2000) . During the stepwise transition from normal melanocytes to RGP, VGP and metastatic melanoma, the transformed cells interact with their microenvironmental components such as keratinocytes, fibroblasts, endothelial cells and extracellular matrix (Hsu et al., 2000a; Li et al., 2001a Li et al., , 2002 . These microenvironmental factors form a distinct context that may either inhibit (Hsu et al., 2000b) or promote tumorigenesis (Hsu et al., 1998; Li et al., 2001a) , depending on the nature of the interactions (Bissell and Radisky, 2001; Li et al., 2002) .
Cell adhesion molecules (CAMs) involving homophilic and heterophilic cell-cell interactions have been suggested to play important roles in organogenesis and maintenance of tissue integrity (Armstrong, 1989) . Aberrant expression of different CAM is a contributing factor to tumor development and progression (Johnson, 1992; Li et al., 2002) . MelCAM (MUC 18, CD146) is an integral membrane glycoprotein with an apparent molecular weight of 113 kDa and possesses several protein kinase recognition motifs in its cytoplasmic domain , suggesting a potential involvement of the cytoplasmic region in cell signaling . It has been shown that activated MelCAM forms a complex with Fyn and activates FAK (Anfosso et al., 1998) . Therefore, complex formation involving MelCAM, Fyn, FAK, and paxillin is thought to promote focal adhesion assembly (Anfosso et al., 1998) . MelCAM has been shown to play a critical role in the cell-cell interactions during melanoma development (Lehmann et al., 1987; Johnson, 1999) . MelCAM mediates melanoma cell interactions via heterotypic Ca 2 þ -independent adhesion to a currently undefined ligand (Shih, 1999) . Although not expressed in normal melanocytes and only rarely detected on nevus cells, it is highly expressed by most advanced primary lesions and metastatic melanoma (Johnson, 1992; Shih et al., 1994b; Xie et al., 1997) . MelCAM-negative melanoma cells with a low tumorigenic potential became highly tumorigenic and metastatic upon transfection with MelCAM (Luca et al., 1993; Xie et al., 1997; Satyamoorthy et al., 2001b) . Inhibition of MelCAM in a highly metastatic cell line resulted in reduced invasion and increased apoptosis in artificial skin reconstructs , and decreased tumorigenicity of melanoma cells in mice Mills et al., 2002) . However, the precise events that lead to apoptotic cell death in three-dimensional tissue reconstructs by downregulating MelCAM expression , and in tumor-bearing mice treated with anti-MelCAM antibody (Mills et al., 2002) remain unclear.
In light of its functional importance in tumorigenesis, especially in melanoma development, several lines of studies are underway to understand the expression and function regulation of MelCAM. The presence of putative binding sites for the transcriptional factors AP-1, AP-2 and CREB in the promoter region suggests that Mel-CAM expression can be modulated by exogenous factors Xie et al., 1997; Jean et al., 1998) . At the cellular level, phorbol ester and cyclic AMP have been shown to modulate MelCAM expression (Rummel et al., 1996) . Furthermore, expression of MelCAM in melanocytic cells is environmentally regulated by epidermal keratinocytes through direct cell-cell contacts (Shih et al., 1994a; Hsu et al., 2000b; Li et al., 2002) . However, how the regulation occurs under physiological and pathological conditions during melanoma progression, and how it correlates with other molecular and cellular changes in melanocytic tumorigenesis remain mainly elusive.
AKT (also known as protein kinase B, PKB), the cellular homolog of the retroviral oncogene v-AKT (Bellacosa et al., 1991) , encodes a serine/threonine kinase. AKT is activated by a dual regulatory mechanism that requires both translocation to the plasma membrane and phosphorylation at Thr308 and Ser473 (Andjelkovic et al., 1997; Aoki et al., 1998; Bellacosa et al., 1998) . Upon activation, AKT acts to promote cell survival (Vivanco and Sawyers, 2002) , proliferation and growth (Diehl et al., 1998) and angiogenesis (Shiojima and Walsh, 2002) . Especially, AKT plays a critical role in survival when cells are exposed to proapoptotic stimuli such as growth factor withdrawal, irradiation, detachment, DNA damage and administration of apoptosis-inducing reagents (Datta et al., 1999; Vivanco and Sawyers, 2002) . The mechanisms of AKT-mediated protection from cell death appear to be multifactorial, as suggested by the fact that AKT directly phosphorylates multiple components of the cell death machinery, which in turn act on cascades of other effectors (Vivanco and Sawyers, 2002) . Although AKT overexpression or activation has been documented in various human tumors (Nicholson and Anderson, 2002) , the role of AKT activation in melanoma is not well studied. Screening of pleckstrin homology (PH) domain (Waldmann et al., 2002) and codons 308 and 473 (Waldmann et al., 2001) of AKT yielded no mutations. Loss of function of PTEN, an upstream negative regulator of the PI3K-AKT pathway, has been linked to certain sporadic melanoma development; however, recent studies have downplayed the importance of the gene in human melanoma (Pollock and Trent, 2000; Poetsch et al., 2001) . Our previous studies have demonstrated AKT involvement in N-cadherin-mediated cell survival and autocrine HGF-induced dissociation in melanoma (Li et al., 2001b) .
In this study, we identify AKT as the pivotal molecule that mediates both inside-out and outside-in signaling pathways involving MelCAM. Constitutive activation of AKT was observed in both melanoma cell lines and tumor samples. Inhibition of AKT activation led to reduced expression of MelCAM, while superactivated AKT resulted in increased MelCAM expression. On the other hand, overexpression of MelCAM in melanoma cells led to further activation of AKT, resulting in increased cell survival under stress conditions. These data suggest that inhibition of the AKT pathway may prove to be a valid therapeutical approach to melanoma.
Results
Akt is constitutively activated in melanoma cell lines and tumor samples, but not in normal melanocytes
Oncogenic kinase activation plays a central role in tumor initiation and progression (Blume-Jensen and Hunter, 2001) . Constitutive activation of the MAP kinase pathway has been identified in human melanoma as a result of BRAF-activating mutations (Davies et al., 2002; Satyamoorthy et al., 2003) and autocrine growth factor stimulation (Satyamoorthy et al., 2003) . The activation of MAP kinase and its downstream effectors in melanoma may support the autonomous growth of cancer cells, leading to uncontrolled proliferation, a hallmark of tumorigenesis. Furthermore, it has been shown that sustained activation of the MAP kinase pathway increases the expression of b3 integrin (Woods et al., 2001) , a molecule correlated with the acquisition of invasive behavior by melanoma cells (Albelda et al., 1990; Hsu et al., 1998) . Despite ample studies on the role of the PI3K-AKT pathway in various cancers (Aoki et al., 1998; Nicholson and Anderson, 2002) 
AKT activity regulates MelCAM expression in melanoma cells
It has been shown that continuous activation of the MAPK pathway induced b3 integrin expression in melanoma (Woods et al., 2001) . However, it is not clear whether AKT activation plays a role in the regulation. Besides b3 integrin, we were also interested to know whether MelCAM, another melanoma metastasis marker (Shih, 1999) , is regulated by either MAPK pathway or PI3K-AKT pathway, or both. To address these questions, various pharmacological reagents with known specificities were used to treat melanoma cells and expression levels of b3 integrin and MelCAM were monitored by both FACS and Western blotting. To establish the appropriate dosages for the treatment, we treated four melanoma cell lines, WM35 (RGP), WM1341D (RGP/VGP), WM793 (VGP) and WM852 (metastatic), with PI3K pathway inhibitor wortmannin at 4 and 40 mm, or with MAPK pathway inhibitor PD98059 at 10 and 40 mm (data not shown). After 24 and 48 h, cell viability was assayed by trypan blue exclusion. Wortmannin at 40 mm caused substantial death, while PD98059 at the same dosage had much less effect on cell viability. Based on this information, we chose 4 mm wortmannin and 40 mm PD98059 as the working concentrations to be used in b3 integrin and MelCAM screening.
Four melanoma cell lines representing different progression stages, as described above, were treated with either 4 mm wortmannin or 40 mm PD98059 for 48 h. Floating dead cells were washed away before cell lysis in RIPA buffer. Cell lysates were then analysed by SDS-PAGE and Western blotting (Figure 3a) . Wortmannin treatment substantially reduced the protein levels of MelCAM in all the four cell lines to various extents, while PD98059 had no effect on MelCAM. The activation (phosphorylation) status of AKT matched the expression levels of MelCAM, suggesting an inherent linkage between these two molecules. On the other hand, b3 integrin expression was affected by PD98059 treatment, consistent with a previous report (Woods et al., 2001) . The effects of wortmannin and PD98059 were also evident by FACS analyses (Figure 3b ). To further confirm the action of the PI3K-AKT pathway on MelCAM expression, adenoviruses expressing active AKT (Myr-AKT) (Kohn et al., 1996) or dominant-negative PI3K (Dp85) (Oka et al., 2000) were administered to WM793 (Figure 4 ). Western blotting clearly showed that while activation of AKT (Myr-AKT) increased MelCAM expression, inhibition of AKT activity by a dominant-negative PI3K reduced MelCAM protein level, consistent with the pharmacological inhibition assay (Figure 3 ).
MelCAM expression promotes AKT activity and cell survival
MelCAM possesses conserved protein kinase recognition motifs in its cytoplasmic domain , suggesting a potential involvement in intracellular signaling. To test whether MAPK and/ or PI3K-AKT pathways were activated following MelCAM expression/activation, a panel of melanoma cell lines were transduced with MelCAM-expressing adenovirus (MelCAM/Ad5) . MelCAM/Ad5 transduction led to increased cell surface expression of MelCAM (not shown). Following MelCAM expression, a significant increase in the amounts of phosphorylated AKT (Ser473 AKT) was observed in all cell lines tested (Figure 5a ), accompanied by the phosphorylation (inhibition) of proapoptotic protein BAD (Datta et al., 1997) (Figure 5a ). On the contrary, the levels of phosphorylated MAPK were slightly decreased in MelCAMtransduced cell lines (Figure 5a ). Wortmannin was able to inhibit AKT phosphorylation at Ser473 induced by MelCAM overexpression in SBcl2 (Figure 5b ), WM35 and WM793 (not shown).
MelCAM overexpression had no effect on cell proliferation in vitro . When cell death was induced in melanoma cells by staurosporine, MelCAM-transduced cells showed higher resistance to the drug, compared with those transduced with control adenovirus LacZ (Figure 6a ). The increased survival of MelCAM-transduced melanoma cells was Figure 1 Constitutive activation of AKT and MAPK in melanoma cell lines, but not in melanocytes. Normal human melanocyte (FOM73) and melanoma cell lines representing radial growth phase (RGP), vertical growth phase (VGP) and metastatic phase were cultured in media containing 0, 0.5 and 2% serum for 48 h. Cells were lysed in RIPA buffer and cell lysates were subject to Western blotting. The presence of AKT, phospho-AKT, MAPK and phospho-MAPK was detected using specific antibodies. A single blot representative of three repeats is shown Reciprocal regulation of MelCAM and AKT G Li et al also manifested by the resistance of caspase 3 cleavage, an early event during apoptosis, in these cells (Figure 6b ).
MelCAM does not physically interact with PI3K
A previous study has shown that activated Mel-CAM forms a complex with Fyn and activates FAK, thereby promoting focal adhesion assembly (Anfosso et al., 1998) . It has also been shown that certain cell surface molecules, such as estrogen receptor a (ERa), activate the PI3K-AKT pathway by directly binding to the p85a regulatory subunit of PI3K upon receptor activation (Simoncini et al., 2000; Sun et al., 2001) . However, using either anti-MelCAM or anti-p85a antibody, we were not able to detect any direct binding between these two molecules (not shown). MelCAM did not coimmunoprecipitate with p110 either (not shown). suggested that MelCAM is a valid therapeutical target for melanoma. However, the lack of mechanistic understanding of its regulation and function has posed a major difficulty in further exploring its usefulness in melanoma treatment. In this study, we provide evidence that cell adhesion molecule MelCAM and kinase AKT are reciprocally regulated, forming a bidirectional signaling network. Specifically, we show the following: Satyamoorthy et al., 2003) contribute to the constitutive activation of MAP kinase (ERK1/2). In this study, we extend our previous observation (Li et al., 2001a, b; Satyamoorthy et al., 2001a ) that the PI3K-AKT pathway may also play a role in melanoma development. The PI3K-AKT signaling pathway, parallel to the RAS-RAF-MAPK pathway, is a pivotal mediator of extracellular stimuli, including growth factors, cytokines, cell-cell adhesion and cell-extracellular matrices (Downward, 1998; Vivanco and Sawyers, 2002) . Upon activation, AKT phosphorylates and regulates the function of many cellular proteins involved in processes that include metabolism, apoptosis and proliferation. Recent evidence indicates that AKT is constitutively active in many types of human cancer (Nicholson and Anderson, 2002) , thereby contributing to cancer progression. The observation that melanomas contain both activated MAPK and AKT suggests that effective therapeutical targeting may involve both MAPK and AKT pathways. For instance, as shown in this and other studies (Woods et al., 2001) , MelCAM is regulated by the PI3K-AKT pathway and not by the MAPK pathway, and b3-integrin is regulated by the MAPK pathway and not by the AKT pathway. Therefore, in order to quench both MelCAM and b3-integrin, one may need to inhibit simultaneously both MAPK and AKT. Intriguingly, E-cadherin-mediated cell-cell inter- 
Discussion
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action between keratinocytes and melanoma cells in coculture leads to simultaneous downregulation of both MelCAM and b3-integrin (Hsu et al., 2000b) . The detailed mechanisms of the downregulation and the effects of coculture on MAPK and AKT status remain to be investigated.
Cell adhesion molecules not only serve as the glue between cells, but also actively participate in transmembrane signaling transduction pathways. It has been well established that cadherin and integrin families of adhesion molecules are involved in both inside-out and outside-in signaling processes. We show in this study that MelCAM also participates in bidirectional regulation. Activation of the PI3K-AKT pathway within the cell can upregulate cell surface expression of MelCAM (inside-out), and cell surface expression of MelCAM can activate PI3K-AKT pathway, leading to increased resistance to proapoptotic stimuli (outside-in). The outside-in signaling pathway downstream of Mel-CAM has been reported in human endothelial cells (Anfosso et al., 1998) . There are significant similarities between malignant melanoma cells and endothelial cells (Maniotis et al., 1999; Folberg et al., 2000; Hendrix et al., 2001; Hess et al., 2001; Li et al., 2001a) , and MelCAM is among the hallmark molecules of human melanoma that can also be found on endothelial cells (Shih, 1999) . The regulation and action of MelCAM and its signaling connection with PI3K-AKT in vascular endothelial cells remain to be investigated.
MelCAM mediates calcium-independent homotypic melanoma cell adhesion (Shih et al., 1997; Xie et al., 1997) as well as heterotypic melanoma-endothelial and melanoma-melanoma cell adhesion Shih et al., 1997) through an as yet unknown ligand. Using cell mixing and solid-phase adhesion assays, Shih et al. (1994b Shih et al. ( , 1997 have shown that MelCAM ligand, although unknown, is expressed by most melanoma cells, including those cell lines used in this study. However, it is not clear whether activation of AKT by MelCAM is ligand-dependent, because overexpressed cell surface molecules may cluster in the absence of ligand binding. Since currently no effective MelCAM-blocking antibody is available, and the identity of the ligand is unknown, this question cannot be directly addressed at this time.
We show that MelCAM is a survival factor for melanoma by activating antiapoptotic AKT and inhibiting proapoptotic protein BAD. Although previous studies Mills et al., 2002) have hinted at the antiapoptotic role of MelCAM in melanoma, this study for the first time provides a direct evidence by linking MelCAM to PI3K-AKT activation. Using a MelCAM-specific genetic suppressor element (GSE), Satyamoorthy et al. (2001b) showed that inhibition of MelCAM increased apoptosis in organotypic skin reconstructs. Growth was not inhibited in GSE-treated melanoma cells cultured in monolayers, but was inhibited when cells were maintained anchorage-independently in soft agar and greatly reduced in immunodeficient mice , suggesting that MelCAM mainly affects survival. Using a different approach involving a fully human antiMelCAM antibody, Mills et al. (2002) showed that the antibody had no effect on melanoma cell proliferation rate in vitro. When cells were injected into nude mice and treated with ABX-MA1, tumor growth was significantly inhibited and the number of tumor cells undergoing apoptosis was higher (Mills et al., 2002) . Our results convincingly provide a mechanistic explanation for the above-observed effects.
Direct physical interaction between MelCAM and PI3K was not observed in this study. Although some signaling molecules are activated by direct binding to the cell surface receptors, other signaling molecules do not appear to bind directly to the receptor itself. For example, ERa activates the PI3K pathway by directly binding to the p85a regulatory subunit of PI3K upon activation (Simoncini et al., 2000; Sun et al., 2001) . On the other hand, EGF receptor (EGFR) does not appear to bind PI3K directly, yet stimulation of EGFR leads to PI3K-AKT activation. Recent studies have shown that scaffolding molecules such as insulin-regulated substrate-1 (IRS-1) (White and Kahn, 1994) , Gab1/2 (Rudd, 1999) and c-Cbl (Liu and Altman, 1998; Kassenbrock et al., 2002) may function in cooperation with cell surface receptors to regulate downstream signaling molecules that do not bind directly to the receptors. Alternatively, it has been shown that activation of MelCAM in endothelial cells induced association of Fyn with MelCAM, resulting in the phosphorylation of FAK and its binding with paxillin (Anfosso et al., 1998) . Whether activation of Fyn or other Src-related molecules is directly responsible for AKT activation in melanoma cells is under investigation.
The work presented here attributes an unrecognized signaling axis between MelCAM and AKT. The data suggest that activation of AKT pathways in melanoma leads to potentiation in cell adhesion, migration and invasion during melanoma tumorigenesis, and the migration/invasion process, in return, further activates the PI-3 kinase/AKT pathway, leading to enhanced migration/invasion and survival. The study implicates that intervention of MelCAM-AKT signaling in melanoma may be a valid therapeutical approach.
Materials and methods
Cell culture
Human melanoma cells were isolated from clinically and histologically defined lesions (Satyamoorthy et al., 1997; Hsu et al., 1999) . After establishment of continuous growth, cells were maintained in medium W489, a 4 : 1 mixture of MCDB153 and L15, supplemented with 2% heat-inactivated fetal bovine serum (FBS) and insulin (5 mg/ml) in a 371C, 5% CO 2 atmosphere at constant humidity. For growth in proteinfree (PF) media, FBS and insulin were omitted from the medium. Human melanocytes were isolated from foreskin and maintained in MCDB153 medium supplemented with FBS, endothelin-3 (ET-3) and stem cell factor (SCF) (Berking and Herlyn, 2001) . Human keratinocytes were isolated from foreskin and maintained in SFM (GIBCO BRL, Gaithersburg, MD, USA). Transcomplementing 293 cells, a cell line immortalized and transformed by adenovirus E1a and E1b, were obtained from the Vector Core at the Institute for Human Gene Therapy (University of Pennsylvania, Philadelphia, PA, USA) and grown in DMEM with 10% FBS. All tissue culture reagents were purchased from Sigma Chemical Co. (St Louis, MO, USA) and GIBCO BRL (Gaithersburg, MD, USA).
Antibodies and reagents
Mouse anti-b-actin antibody was purchased from Sigma (St Louis, MO, USA). Rabbit anti-aspase 3, anti-AKT, antiphospho-AKT, anti-Bad, anti-phospho-Bad, anti-p44/42 MAPK and anti-phospho-p44/42 MAPK (Thr202/Tyr204) antibodies were purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA). Mouse mAb A32 (IgG 1 ) against MelCAM/MUC18 was previously characterized (Shih et al., 1994b) . Mouse anti-b3 integrin, anti-p110 (PI3K), anti-p85 and anti-MelCAM antibodies were purchased from Transduction Laboratories, Inc. (Lexington, KY, USA). Inhibitors PD98059 and wortmannin were purchased from Sigma (St Louis, MO, USA).
Adenoviral vectors
Adenoviral vector for MelCAM has been described . Adenoviral vectors Myr-AKT and Dp85 were kindly provided by Dr Masahiro Oka (Sakaue et al., 1997; Kotani et al., 1999; Oka et al., 2000) . Control adenoviral vector containing the LacZ cDNA (lacZ/Ad5) was purchased from Vector Core at the Institute for Human Gene Therapy of the University of Pennsylvania (Philadelphia, PA, USA). Plaque-purified virus propagated in 293 cells was purified by ultracentrifugation in a cesium chloride gradient. Viral titer was assayed by plaque formation in permissive 293 cells. Subconfluent (80%) melanoma cells were infected at 20 pfu/ cell with replication-deficient adenoviruses for 4 h at 371C in protein-free medium. Viral suspension was then replaced with regular medium. Cells were allowed to recover for at least 24 h before assay.
Western blotting
Cells were washed with PBS and harvested in RIPA buffer. Total protein concentrations were measured using the bicinchoninic acid (BCA) assay (Pierce Chemical Co Rockford, IL, USA). Samples were loaded at 20 mg/lane and separated on 8-12% SDS-polyacrylamide gels and then transferred to polyvinylidene difluoride (PVDF) membranes and probed with specific primary antibodies. To detect the signal, peroxidase-conjugated secondary antibody was added, followed by exposure using enhanced chemiluminescence (ECL) (Amersham, Arlington Heights, IL, USA).
Cell survival assay
Cell viability was determined in triplicate samples by trypan blue exclusion assay, and death index was calculated as: death index ¼ number of dead cells/total number of cells.
Flow cytometry
Cultured cells were detached with Versene, washed once with PBS and stained for 40 min with primary antibody at 41C with shaking at 150 r.p.m. Cells were then washed and incubated with FITC-conjugated secondary antibody. After extensive washing, cells were analysed by fluorescence-activated cell sorting (FACS). Unrelated mouse IgG was used as a negative control.
Immunohistochemistry
Tissues were collected from the achieved material at the Hospital of the University of Pennsylvania, Philadelphia, PA. All the tissues were fixed in neutral buffered formalin and embedded in paraffin. Sections (4 mm) were cut from a representative paraffin block of each case. Following heat antigen retrieval, sections were stained as described in the manufacturer's brochure (Cell Signaling Technology).
